title: Nonpeptide mimic of bradykinin with long-acting properties.
abstract: Kinins, members of a family of peptides released from kininogens by the action of kallikreins, have been implicated in a variety of biological activities including vasodilation, increased vascular permeability, contraction of smooth muscle cells and activation of sensory neurons. However, investigation of the physiological actions of kinins have been greatly hampered because its effects are curtailed by rapid proteolytic degradation. We examined the pharmacological characteristics of the first nonpeptide bradykinin receptor agonist 8-[2,6-dichloro-3-[N-[(E)-4-(N-methylcarbamoyl)cinnamidoacetyl+ ++]-N-methylamino]benzyloxy]-2-methyl-4-(2-pyridylmethoxy)quinolin e (FR190997). FR190997, whose structure is quite different from the natural peptide ligand, but is similar to the nonpeptide antagonists FR165649, FR167344 and FR173657, potently and selectively interacts with the human B2 receptor and markedly stimulates inositol phosphate formation in transfected Chinese hamster ovary (CHO) cells. FR190997 induces concentration-dependent contraction of isolated guinea pig ileum. In vivo, FR190997 mimics the biological action of bradykinin and induces hypotensive responses in rats with prolonged duration, presumably as a consequence of its resistance to proteolytic degradation. Therefore, FR190997 is a highly potent and subtype-selective nonpeptide agonist which displays high intrinsic activity at the bradykinin B2 receptor. This compound represents a powerful tool for further investigation of the physiology and pathophysiology of bradykinin receptors.
authors.affiliation: Molecular Biological Research Laboratories, Fujisawa Pharmaceutical, Tsukuba, Japan. ichiro_aramori@po.fujisawa.co.jp
authors.forename: I
authors.initials: I
authors.lastname: Aramori
authors.forename: J
authors.initials: J
authors.lastname: Zenkoh
authors.forename: N
authors.initials: N
authors.lastname: Morikawa
authors.forename: M
authors.initials: M
authors.lastname: Asano
authors.forename: C
authors.initials: C
authors.lastname: Hatori
authors.forename: H
authors.initials: H
authors.lastname: Sawai
authors.forename: H
authors.initials: H
authors.lastname: Kayakiri
authors.forename: S
authors.initials: S
authors.lastname: Satoh
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Abe
authors.forename: Y
authors.initials: Y
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Mizutani
authors.forename: N
authors.initials: N
authors.lastname: Inamura
authors.forename: M
authors.initials: M
authors.lastname: Iwami
authors.forename: K
authors.initials: K
authors.lastname: Nakahara
authors.forename: H
authors.initials: H
authors.lastname: Kojo
authors.forename: T
authors.initials: T
authors.lastname: Oku
authors.forename: Y
authors.initials: Y
authors.lastname: Notsu
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000378:metabolism*; D016466:CHO Cells; D006224:Cricetinae; D019204:GTP-Binding Proteins / Q000819:agonists / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D006868:Hydrolysis; D007275:Injections, Intravenous; D018716:Molecular Mimicry; D010455:Peptides / Q000494:pharmacology*; D011485:Protein Binding; D011804:Quinolines / Q000008:administration & dosage / Q000378:metabolism; D018002:Receptors, Bradykinin / Q000819:agonists / Q000096:biosynthesis / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000819:agonists
chemical_list: C107104:FR 190997; D010455:Peptides; D011804:Quinolines; D018002:Receptors, Bradykinin; D011956:Receptors, Cell Surface; D019204:GTP-Binding Proteins; D001920:Bradykinin